The Yersinia outer protein (Yop) M effector from the Yersinia pestis bacterium is well-known for being a critical virulence determinant; however, structural insight vis-à-vis its role in Y. pestis pathogenesis has been elusive. Here, we investigate the intact sequence of the YopM protein through our recently developed fold identification and homology modeling tools, and analyze the immune modulatory potential of its constituent domains. We identify a putative novel E3 ligase (NEL) domain towards the C-terminal tail of YopM and characterize its active site, to show that YopM could function as an autoregulated bacterial type E3 ubiquitin ligase. We further identify unreported NEL domains in several other bacteria and note remarkable similarity in sequence, structure, surface, and electrostatics for the family of NEL-containing bacterial effectors that suggests conserved function and potentially similar host targets for these proteins. Based on these observations and recent empirical evidence for degradation of the human proteins HLA-DR, thioredoxin, and NEMO/IKKg by other members of the NEL-containing bacterial family, we discuss the potential for YopM to modulate a wide spectrum of immune signal transduction pathways. The key immune modulatory effects highlighted are suppression of MHC class II antigen presentation, dampening of nuclear factor (NF)-kB mediated inflammatory response, and intonation of mitogen-activated protein kinase (MAPK) signaling. Additionally, our analysis of the modeled YopM LRR domain reveals structural features akin to the Toll-like receptor 4 (TLR4) LRR motif. We propose that YopM LRR could be a 'molecular mimic' of TLR4 LRR, permitting reduced immunogenicity and potentially mitigating bacterial lipopolysaccharide surveillance of the innate immune system. Our identification and characterization of the YopM NEL domain, taken together with our analysis of the YopM LRR domain, provides plausible insight into subversion of host immunity by Y. pestis YopM and perhaps could set the stage for design of new therapeutic opportunities.
Introduction
Human infection with Yersinia pestis has resulted in several major epidemics throughout recorded history, including the bubonic plague that was responsible for the death of nearly one-third of Europe's population in the mid 14th century. 1 Yersinia pestis pathogenesis in humans is the combined result of numerous factors that contribute to bacterial infection, systemic invasion, potent virulence, and human-to-human transmission. [2] [3] [4] A chief component of Y. pestis pathogenesis is the bacterium's ability to impair key immune system functions such as antibody production and phagocytosis. [5] [6] [7] Yersinia pestis produces two anti-phagocytic antigens -Fraction 1 (F1) and LcrV (V) -that are key virulence factors. Additionally, Y. pestis injects Yersinia outer protein (YOP) effectors via the type-III secretion system (T3SS) into the cytoplasm of host macrophages and other immune cells, thereby impeding phagocytosis and encumbering many of the cell signaling pathways of the innate immune system. 8, 9 Yersinia outer protein M (YopM) is an effector that is essential for virulence of the pathogen. 10 Although YopM is a key player in Y. pestis pathogenesis, a coherent picture accounting for the full spectrum of anti-host functions of YopM is only beginning to emerge. 11 Towards this, recent studies have demonstrated diversity in localization and potential interactions of YopM. [12] [13] [14] These studies underline the need for deriving the molecular structure of YopM and analyzing the structural features that contribute to its function as a key Y. pestis virulence factor. The YopM molecular structure consists of a leucine-rich repeat (LRR) domain, in addition to a short C-terminal tail (that encodes information pertinent to secretion and translocation of YopM) and an N-terminal tail with hitherto unknown functions. While fragments of the YopM molecule have been crystallized, 11 there are currently no reports on the structure of the intact YopM molecule that can permit analysis of the function of YopM domains in an integrated fashion.
In this study, we analyze the structure of the intact YopM molecule, obtained by our recently proposed fold identification and homology-based (comparative) modeling tools, 15 using the related high-identity structures of effector proteins from Salmonella and Shigella as templates (see Materials and methods). From this analysis, we identify the YopM NEL domain and the enzyme active site of this autoregulated type E3 ubiquitin ligase. The identified YopM NEL domain, located towards the C-terminal tail of the protein, has high surface similarity to Shigella and Salmonella effector NEL domains, with several prominent, well-conserved patches in addition to the active site. We further find remarkable similarity for the entire spectrum of NELbased effector family from Gram-negative bacteria that possess the Type III secretion system (T3SS), including Yersinia, Salmonella, Shigella, enteroinvasive Escherichia coli, and Pseudomonas. These findings suggest a common mode of NEL-driven host protein degradation by these pathogenic bacteria. The conserved bacterial NEL fold further appears distinct from the known mammalian ubiquitin ligases and other mammalian proteins, thus presenting exciting opportunities for the development of broad-spectrum antibacterial therapeutics that target the NEL active site. We also map the potential host intracellular molecules that are targets of bacterial proteolysis, such as HLA-DR, thioredoxin, and NEMO/IKKg. From this analysis of the YopM LRR domain, we note that this is one of the closest structural neighbors to human Toll-like receptor 4 (TLR4) LRR domain, despite minimal sequence identity between these proteins. We further observe similar electrostatic surfaces between these molecules in the proximity of the MD2-LPS recognition site of TLR4, thus suggesting that YopM may be a potential 'molecular mimic' of TLR4. We conclude with a discussion on the prospective immune modulatory effects relating to potential YopM mimicry of TLR4, including suppressed immunogenicity and subversion of the innate immune machinery's LPS surveillance systems.
Materials and methods
The molecular structures of NEL domains from Y. pestis YopM (NCBI Reference Sequence: ZP_02316950.1) and Salmonella enterica sv. Typhimurium SlrP (GenBank: AAD39928.1) were identified and modeled using the protein core atomic interaction network (PCAIN) methodology, 15 
Results and discussion
Identification of the YopM NEL domain, an autoregulated ubiquitin ligase, belonging to a highly conserved bacterial effector family with a wide spectrum of host immune modulatory properties There is an emerging understanding that bacterial NEL domains function as autoregulated ubiquitin ligases, supplemented by binding of adjacent LRR domains to key host molecules, for mitigation of host immunity. 16, 17 The crystal structures of NEL domains from Shigella IpaH9.8 (PDB ID: 3CKD) and Salmonella SspH2 (PDB ID: 3G06) have recently been determined, 18, 19 and there is remarkably high sequence identity and conservation of potential core residues between the C-terminal tail of Y. pestis YopM, Shigella IpaH9.8, Salmonella SspH2, and Salmonella SlrP (Fig. 1A) . Building on this observation, the structures of the Shigella and Salmonella effectors were used as templates for homology-based modeling of the intact YopM molecular structure (see Materials and methods).
Analysis of the NEL domains from Salmonella SspH2, Salmonella SlrP, Shigella IpaH9.8, and the newly identified Y. pestis YopM reveals high conservation of molecular surface electrostatics, including several highly conserved patches ( Fig. 1B) . Specifically, the putative ubiquitin ligase catalytic site on the YopM NEL domain is distinctly recognizable (Fig. 1C ) and conserved across all known bacterial NEL domains ( (Table 1) . Also, most of the NEL-based autoregulated ubiquitin ligase protein-containing bacteria are pathogenic or opportunistic to humans, being implicated in a number of diseases ( Table 2) .
Analysis of the modeled YopM NEL domain structure shows that the putative ubiquitin ligase active site is present on the NEL-LRR interface (Fig. 1C ), similar to the previously characterized NEL active site structures from Salmonella and Shigella. 16, 17, 20 The hydrogen bonds that stabilize the active site, mainly occur between residues of the key a-helices H4, H7, and H9, and are also conserved across the NEL-containing bacterial effector family (Fig. 1C) . Specifically, the key active site cysteine (Cys407) that has been implicated in loss of enzyme function upon mutation (to alanine or serine) in Shigella, 20 is distinctly recognizable in the well-conserved solvent-exposed loop proximal to the NEL-LRR interface, where it is stabilized by a dense hydrogen bond network (Fig. 1C) . The solventexposed residues in the immediate vicinity of the YopM NEL active site contribute to stabilization of the Cys407-containing loop via hydrogen bond Table 1 . Conservation of residues constituting the ubiquitin ligase active site for the effector protein NEL domains from Salmonella, Shigella, Yersinia, Escherichia, and Pseudomonas. The corresponding active site rendering and multiple sequence alignment for Salmonella, Shigella, and Yersinia effector protein NEL domains is provided in Figure 1 Bacterium Effector protein Sequence Accession Number
NEL domain active site residues networks including Glu408, Asp409, Arg448, and Asp472 ( Table 1 ). The other residues in the vicinity of the active site cysteine are buried into the NEL domain core and include Trp345, Leu440, Ala457, Leu479, Leu489, and Leu491. These hydrophobic residues are highly conserved in the NEL family ( Fig. 1A) given their likely key role in folding of the NEL domain. Additionally, Asn469 and Arg362 occur distinctively in Y. pestis YopM, likely for supplementary stabilization of the active site helices and loops. The highly conserved NEL fold and active site presents exciting opportunities for targeting antibacterial therapeutics for the treatment of a wide spectrum of diseases ( Table 2 ). Such therapies are likely to be particularly effective given that NEL-containing effectors are critical virulence determinants. 10 Furthermore, we note that bacterial ubiquitin ligases like YopM NEL are not homologous in sequence or structure to the more commonly known mammalian ubiquitin ligases such as HECT type and RING type families. 17 We also note that the YopM NEL domain has no known mammalian structural neighbors ( Table 3 ). The high conservation of the bacterial NEL domain taken together with the absence of mammalian homologs underlines the potential for development of NELtargeting therapeutics.
Next, we proceeded to derive insight into the putative functions of YopM NEL from analysis of our structural model and its close homologs. First, YopM has been shown by various studies to interact with the host proteins protein kinase C-related kinase 2 (PRK2), ribosomal s6 kinase 1 (RSK1), interleukin-15 (IL-15), and a 1 -antitrypsin (AAT). [12] [13] [14] Particularly, the C-terminal tail of YopM was recently shown to be critical for interacting with RSK1 and for virulence; 21 however, the rationale underlying these observations remains unknown. With the identification and characterization of the YopM NEL domain in the C-terminal tail of YopM presented in this study, it appears plausible that the suggested autoregulated ubiquitin ligase activity associated with this region may contribute to the observed virulence of YopM.
Next, the remarkable similarity in sequence, structure, fold, surface, and electrostatics, between the bacterial NEL domains (Fig. 1) , suggests conserved functions and potentially similar host targets for this effector family. Given that the well-characterized YopM homologs from Salmonella and Shigella are autoregulated E3 ubiquitin ligases which proteolyze key host immune system molecules such as HLA-DR, NEMO, and thioredoxin (TRX), 16, 17, 20 it appears plausible that YopM NEL may also modulate human immunity ( Fig. 2A) . For instance, a recent study has shown that the YopM homolog Shigella IpaH9.8 is involved in the degradation of NEMO/IKKg (Fig. 2B) , thus causing dampening of the nuclear factor (NF)-kB based inflammatory response and compromised host innate immunity. 20 The residues on IpaH9.8 that bind to NEMO were not characterized in that study. However, the structural and surface similarity between YopM and Shigella IpaH9.8 (Fig. 1B) suggests an investigation of NEMO engagement and innate immune subversion by YopM during Y. pestis infection ( Fig. 2A) . Similarly, Salmonella type III secretion effector SlrP, another YopM homolog (Fig. 1B) , is involved in the degradation of mammalian thioredoxin (Fig. 2B ). 16 Thioredoxin interacts with mitogen-activated protein kinase 5 (MAPK5), 22 an important regulator of immune signal transduction via the MAPK cascade. Similar to the IpaH9.8 study, however, the SlrP study also did not recognize the Slrp-TRX binding site; therefore, examination of conservation of those residues between YopM and SlrP is beyond the scope of the current study. Nevertheless, the high similarity between YopM and SlrP suggests that modulation of MAPK signaling pathways by YopM may be another mode by which Y. pestis could potentially alter host innate immune response ( Fig. 2A) . Additionally, it has also been shown that Salmonella effectors ubiquitinate and degrade the major histocompatibility complex (MHC) class II receptor HLA-DR ( Fig. 2B ) within antigen-presenting host cells like macrophages, B-cells, and dendritic cells. 16 Degradation of HLA-DR has been shown to diminish MHC class II antigen surface expression, thus promoting temperance of host adaptive immunity ( Fig. 2A) . The similarity between the Salmonella and Yersinia effectors suggests that it may be prudent to evaluate HLA-DR concentrations during Y. pestis infection. It may be noted that the NEL-based immune modulatory functions for YopM Figure 2 . Mapping the potential interactions of bacterial NEL-containing effectors such as Y. pestis YopM with key host proteins to understand their implications for modulation of host adaptive and innate immune signaling. (A) YopM has been shown to interact with protein kinase C-like 2 (PRK2) and ribosomal S6 protein kinase 1 (RSK1) resulting in increased activity and mobility of these kinases, in addition to potentiating NK cell depletion by suppressing expression of interleukin-15 (IL-15). 13 YopM has also been shown to interact specifically with a 1 -antitrypsin (AAT) without affecting its anti-protease activity, due to which the biological significance of this interaction remains unknown. [12] [13] [14] Based on our analysis of the YopM NEL domain ubiquitin ligase active site, we further suggest that host proteins such as human leukocyte antigen-DR (HLA-DR), thioredoxin (TRX), and NEMO which are known to interact with other bacterial effectors (and are ubiquitinated by them) are possible targets. As depicted, degradation of NEMO and TRX could cause acute suppression of host innate immunity. All predicted interactions that require empirical corroboration are indicated as by the question mark (?) symbol. (B) Shown herein for reference, are the structures of the known host target proteins for the NEL-containing bacterial effector family.
are all novel vis-a`-vis Y. pestis, and are over and above the known host subversive functions for the several other Yop effectors. 8, 9 It may also be noted that since NEL and LRR domains are generally known to function in an integrated fashion, 16, 17, 20 future studies could investigate the specific functions of these domains in the context of YopM interactions with host intracellular proteins.
We believe that the modeling of intact YopM and structural findings presented herein, will help to promote empirical studies for corroborating the hypothesized interactions and speculated immune modulatory mechanisms ( Fig. 2A) , thus furthering our understanding of the mechanisms governing Y. pestis subversion of host immunity.
Structure of the YopM LRR domain suggests mimicry of TLR4 as rationale for poor TLR4 stimulation by Y. pestis LPS leading to compromise of host innate immunity
There is an emerging understanding that molecular mimicry of immune proteins by bacterial effectors may be important for the disruption of sensors critical to the function of host innate immune machinery. 23, 24 As mentioned earlier, for the Y. pestis YopM protein, there are no known mammalian structural neighbors for the NEL domain (Table 3 ). However, it is of interest to note that the adjoining LRR domain is a structural neighbor of mammalian proteins that are chief moderators of innate immunity (Table 4) . Specifically, we find that the YopM LRR domain (PDB ID: 1JL5) ranks as one of the closest known structural neighbors to the extracellular human TLR4 LRR motif, despite just 12% sequence identity between TLR4 and YopM. Although LRR extensively occurs as a protein-protein interaction motif in several systems such as ribonuclease inhibitors and tropomyosin regulators, 25 the observation of Y. pestis YopM LRR being a structural neighbor of TLR4 LRR is significant given that the TLR4 LRR motif is the key lipopolysaccharide (LPS) sensor in bacterial surveillance. 26 To analyze the structural similarities and distinctions between YopM and TLR4, molecular surface electrostatics were computed from the superposed LRR domains of YopM and TLR4 (see Materials and methods). The structural correlation between YopM LRR and TLR4 LRR was seen to be accentuated by good electrostatic compatibility in the MD2-LPS recognition site of TLR4 albeit distinctions in other sites (Fig. 3A ), suggesting the intriguing possibility of 'molecular mimicry' 24 of host TLR4 by Y. pestis YopM (Fig. 3B ). Superposition of YopM LRR onto TLR4 LRR of the TLR4-MD2 complex (see Materials and methods) suggests moderately comparable protein-protein interfaces (Table 5) , with TLR4 LRR residues that engage MD2-LPS (including Lys362, Lys341, Tyr296, Asp294, Arg264, Lys388, Gln436, Phe440, Phe463, and Leu444) constituting a surface not very different from that of the corresponding surface on YopM LRR (residues include Lys124, Gln142, Asn54, Glu144, Lys145, Ser164, Lys166, Gln184, Asn122, Thr104, Ser102, Glu105, Lys209, Lys208, Glu228, Glu229, Lys250, Pro253, Glu187, Glu190, Asp212, Glu232, and, Lys167). Mutagenesis of these residues in conjunction with testing for immunogenicity and MD2-LPS binding assays may be used by future experimental studies to investigate the potential for structural or functional mimicry of TLR4 by YopM and plausible implications for host immune subversion by Y. pestis thereof (Fig. 3C) .
Specifically, mimicry of the MD2-LPS recognition function of TLR4 by YopM might potentiate its sequestering of tetra-acylated LPS from Y. pestis, 27 or the more common hexa-acylated LPS from other bacteria, 28 such as E. coli (Fig. 3C ). MD2-LPS sequestering by YopM may provide an additional possible mechanistic rationale for poor TLR4 stimulation ability of Y. pestis LPS, over and above the reported absence of TLR4 dimerization upon interaction with the MD2/tetra-acylated Y. pestis LPS complex. [27] [28] [29] In addition to TLR4, LRR domains also occur in other key host immune proteins such as nucleotidebinding oligomerization domain-containing protein (NOD) 1 and NOD2 that are cytoplasmic receptors detecting patterns in microbial molecules for triggering innate immune responses. 30 Given that the functions of NOD proteins are through their C-terminal LRR domains, 30 it is perhaps possible that the YopM LRR domain may act as a 'molecular mimic' of host NODs in the cytoplasm, thus providing additional mechanisms for host innate immune subversion. In support of such a possibility for mimicry of intracellular Figure 3 . Highlighting the potential for molecular mimicry of TLR4 by Y. pestis YopM that could potentiate reduced immunogenicity and subversion of host innate immunity. (A) Vacuum electrostatics of the molecular surfaces from the superposed LRR domains of YopM and TLR4 were generated (see Materials and methods) with negative, positive, and neutral residues colored red, blue, and white, respectively. The conservation of patches corresponding to the MD2-LPS interaction sites for the two LRR domains is also shown (black boxes), as computed from the TLR4-MD2-LPS crystal structure. (B) Shown herein is a hypothetical target molecule engagement by YopM at NEL-LRR interface with MD2-LPS as a representative example. Also shown for reference is the location of the NEL domain active site as identified by our study. MD2-LPS engagement by YopM LRR as depicted herein, provides a structural perspective to the purported molecular mimicry of TLR4 by YopM. (C) YopM has been proposed to interact with a 1 -antitrypsin (AAT) and thrombin (THR) in the extracellular context, [12] [13] [14] for which it is believed to be secreted from the bacteria into the extracellular environment of host cells, as shown. Additionally, TLR4 LRR dimerization that is a result of hexa-acylated LPS (haLPS) stimulation is depicted, along with non-stimulation by tetra-acylated Y. pestis LPS (taLPS). Also shown is the hypothetical MD2-taLPS and MD2-haLPS sequestering of YopM LRR, owing to possible molecular mimicry of TLR4 LRR, that could lead to suppression of host innate immune signaling. The hypothesized interactions that require empirical corroboration by future studies are all indicated by the question mark (?) symbol.
LRR-constituent, host proteins like NOD by YopM (rather than mimicry of extracellular LRR-constituent host proteins like TLR) are the majority of studies on YopM localization that indicate targeted injection of Y. pestis Yops into host cell cytoplasm via T3SS machinery. 8 Decoding the potential for YopM mimicry of NOD or other intracellular host proteins requires derivation of the crystal structures or homology models for the putative target proteins (absent at this time), which could possibly be the focus of future studies.
In addition to possible function mimicry, structural mimicry of host LRR motifs such as TLR or NOD by YopM may by itself be beneficial to the bacterium, from the perspective of dampened immunogenicity owing to highly reduced antigenicity associated with 'self' molecular repertoire. While few studies have detected anti-YopM antibodies in mice and cattle, 31, 32 the cross-reactivity, specificity, and protection offered by such antibodies has not been investigated. More recently, studies have determined that YopM is a poor vaccine candidate since it elicits negligible protective antibody response. 33 Future experimental studies on YopM antigenicity and interactions can shed light on the suggested molecular mimicry of host LRR domains by YopM as incidental, or a more consequential observation.
Conclusions
This study presents an integrated approach to modeling and analysis of the Y. pestis YopM NEL and LRR domains, aimed at deriving structural insight into this multifaceted bacterial effector. This study further highlights the extensive potential for host immune modulation by bacterial NEL-containing effectors that are structurally similar to Y. pestis YopM. Taken together with earlier studies that have examined the NEL-containing effectors from other bacteria such as Salmonella and Shigella, progress is made towards understanding the broad spectrum of bacterial ploys for suppression of host defense, including: (i) dampening of inflammatory response; (ii) intonation of innate immune signaling; (iii) suppression of antigen presentation; (iv) reduced antigenicity; and (v) mitigation of TLR4 surveillance. Finally, this study sets the stage for targeted experiments that could build on the findings presented, to unearth compelling rationale for YopM as a critical virulence determinant. The EBI PISA server was used to characterize the TLR4-MD2 protein-protein interface from the TLR4-MD2-LPS heterodimeric complex (PDB ID: 3FXI), and the predicted YopM-MD2 protein-protein interface from the modeled YopM-MD2 complex, as outlined in Materials and methods. The primary and secondary protein-protein interfaces of both TLR4-MD2 and the putative YopM-MD2 are characterized at the atomic level. It is seen that the primary interface has nearly twice as many atoms and double the contact area as the secondary interface of both protein-protein pairs. Shown herein are the number of interface atoms (N at ), interface residues (N res ), interface area (A 2 ), solvation free energy gain upon interface formation (Á i G kcal/mol), P-value of the observed solvation gain (Á i G P-value), hydrogen bonds (N HB ), salt bridges (N SB ), and disulfide bonds (N DS ).
